Hemostatic Function and Transfusion Efficacy of Apheresis Platelet Concentrates Treated with Gamma Irradiation in Use for Thrombocytopenic Patients

Mei Zhu, Wei Xu, Bao-Long Wang, Hong Su

Department of Nuclear Medicine, The Third Affiliated Hospital of Anhui Medical University,
Department of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University,
Department of Medical Laboratory Medicine, Affiliated Provincial Hospital of Anhui Medical University,
Department of Epidemiology & Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China

Introduction

Allogeneic platelet (PLT) transfusions are fundamental to the supportive care of patients with severe thrombocytopenia, but risks are associated with the use of any blood component...
Transfusion-associated graft-versus-host disease (TA-GVHD) occurs when functional white blood cells (WBCs) are transfused into a patient who is unable to mount an immune response to the allogeneic donor cells due to human leukocyte antigen (HLA) compatibility or to immunosuppression. TA-GVHD is a rare but highly lethal complication caused by engraftment of allogeneic T lymphocytes in the recipient after transfusion of a blood component [3]. Because there is currently no available treatment for TA-GVHD, the goal has been to reduce the likelihood of occurrence. Attempts to reduce these undesirable effects have included exposure of the blood products to gamma irradiation and the use of leukoreduction filters. To date the gold standard for the inactivation of all leukocyte subsets is gamma irradiation [4]. A dose of 25 Gy is commonly used to inactivate viable T cells to prevent TA-GVHD without damaging the platelets [5].

Evaluation of the function of PLTs is only possible by the use of laborious and complicated in vitro tests and markers [6]. Moreover, these in vitro tests do not provide information on the in vivo hemostatic potential of PLTs. In general, hemostatic status has been monitored with plasma-based coagulation tests such as PT/INR and APTT, which underestimate coagulopathy [7]. Moreover, these tests are insensitive for hypocoagulant conditions and thus may be of limited value for the detection of impaired coagulation activity upon dilution [8–10]. Recent studies have shown that hemostatic function after transfusion of apheresis platelet concentrates (PCs) as assessed by whole blood tests (thrombelastography (TEG)). TEG records the viscoelastic properties of clot formation and the quality and stability of the formed clot. TEG provides a rapid assessment of thrombus generation dynamics and fibrinolysis as a real-time graphical display, allowing identification of clinically relevant coagulopathies and guidance of transfusion therapy in various clinical settings [11]. Transfusion efficacy of study arm A and B was evaluated by 1- and 24-hour corrected count increments (CCIs). According to international guidelines, a successful transfusion was defined as a CCI of more than 7.5 for immediate clinical effect (PLT recovery) and a CCI of more than 4.5 for late clinical effect (PLT survival) [2–4, 12–14].

In our study we aim to evaluate and compare hemostatic function, transfusion efficacy, and safety in hematologic patients receiving gamma-irradiated PCs or conventional non-irradiated PCs. Patients were recruited in The First Affiliated Hospital of Anhui Medical University. The study protocol was approved by Anhui Medical University ethics committees, and all patients gave informed consent. Patients admitted for chemotherapy treatment of one of the following conditions, myelodysplastic syndrome, acute myelogenous leukemia, acute lymphoblastic leukemia, multiple myeloma, aplastic anemia and plasma cell leukemia, were enrolled in the study if they were thrombocytopenic or expected to develop thrombocytopenia requiring platelet transfusion.

Exclusion criteria included the following: history of refractoriness to PLT transfusions, presence of HLA antibodies, positive lymphocytotoxicity, or previously documented alloimmunization; disseminated intravascular coagulation; treatment with IL-11 or other investigational platelet growth factors; previous exposure to gamma-irradiated PLTs; active bleeding requiring one or more transfusions of red blood cells (RBCs); coagulation disorders, use of anticoagulants, use of acetylsalicylic acid within the preceding 10 days, or use of non-steroidal anti-inflammatory drugs within the last 24 h; exposure to an investigational product within 30 days before randomization; splenomegaly or splenectomy; history or diagnosis of immune or idiopathic thrombocytopenic purpura, thrombotic thrombocytopenia purpura, or hemolytic uremic syndrome; pregnant or lactating females; any other medical condition that would compromise the participation of the patient in the study. Finally, patients who developed thrombosis, as demonstrated by ultrasonography, were also excluded. Patients were assigned to the study arms based on allocation within the hematologic ward. The ward was divided into a ‘gamma irradiation side’ and an ‘untreated control side’ and only subjects admitted to the gamma irradiation side were asked to participate in the study to receive gamma-irradiated PCs. Patients were assigned to the untreated control side received conventional PCs and served as a control group.

**Material and Methods**

**Study Design and Study Population**

A single-center, randomized design was used in this pilot study to evaluate hemostatic function, transfusion efficacy, and safety of PCs treated by gamma irradiation. The study targeted an enrollment of 40 patients with thrombocytopenia requiring platelet transfusion support. Patients were recruited in The First Affiliated Hospital of Anhui Medical University. The study protocol was approved by Anhui Medical University ethics committees, and all patients gave informed consent. Patients admitted for chemotherapy treatment of one of the following conditions, myelodysplastic syndrome, acute myelogenous leukemia, acute lymphoblastic leukemia, multiple myeloma, aplastic anemia and plasma cell leukemia, were enrolled in the study if they were thrombocytopenic or expected to develop thrombocytopenia requiring platelet transfusion.

Exclusion criteria included the following: history of refractoriness to PLT transfusions, presence of HLA antibodies, positive lymphocytotoxicity, or previously documented alloimmunization; disseminated intravascular coagulation; treatment with IL-11 or other investigational platelet growth factors; previous exposure to gamma-irradiated PLTs; active bleeding requiring one or more transfusions of red blood cells (RBCs); coagulation disorders, use of anticoagulants, use of acetylsalicylic acid within the preceding 10 days, or use of non-steroidal anti-inflammatory drugs within the last 24 h; exposure to an investigational product within 30 days before randomization; splenomegaly or splenectomy; history or diagnosis of immune or idiopathic thrombocytopenic purpura, thrombotic thrombocytopenia purpura, or hemolytic uremic syndrome; pregnant or lactating females; any other medical condition that would compromise the participation of the patient in the study. Finally, patients who developed thrombosis, as demonstrated by ultrasonography, were also excluded. Patients were assigned to the study arms based on allocation within the hematologic ward. The ward was divided into a ‘gamma irradiation side’ and an ‘untreated control side’ and only subjects admitted to the gamma irradiation side were asked to participate in the study to receive gamma-irradiated PCs. Patients were assigned to the untreated control side received conventional PCs and served as a control group.

**Platelet Collection, Preparation, and Study Procedures**

PLTs were collected by standard apheresis procedures (COBE Spectra v.7.0 LRS Turbo and Trima Accel v.5.0 LRS, Gambro BCT, Lake-wood, CO, USA) from 20 healthy donors. Acid-citrate-dextrose (Gambro BCT) was used as an anticoagulant agent. Contaminating WBCs were removed by the leukoreduction system of the cell separators. To avoid reduction in PLT concentration and volume below the requirements and the recommendations of the Chinese guidelines, 20 double-dose single-donor PCs containing more than 250 × 10⁹ PLTs (2.89 ± 0.20 vs. 2.90 ± 0.19, p = 0.989) on the day of donation (day 0) were divided into two study arms (A and B). PCs in study arm A were irradiated with 25 Gy on day 0 (Gamma cell 3000 Elan, MDS Nordion, Ottawa, ON, Canada), PCs assigned to study arm B were used as untreated controls. Gamma-irradiated and non-irradiated PCs were stored in bags being part of each collection kit for the cell separators on an agitator (Model LPR-3, Melco Engineering, Glendale, CA, USA; or Model PFS84, Helmer, Noblesville, IN, USA) in an incubator (Model PC2200, Helmer) at a stable temperature of 22 ± 2 °C under gentle agitation up to 3 days. Gamma-irradiated PCs and non-irradiated PCs were randomly administered to 40 patients.

**Transfusion of Gamma-Irradiated PCs and Non-Irradiated PCs**

ABO- and RhD-identical PLT transfusions were the preferred option and provided whenever possible. PLT transfusions were requested by the patient’s physician in accordance with international guidelines [15–18]. Prophylactic PLT transfusions were given to non-febrile and clinically stable patients with peripheral blood PLT counts below 10 × 10⁹/l and to febrile patients when PLT counts were below 20 × 10⁹/l. In patients with increased risk of bleeding (e.g., before invasive procedures or recent hemorrhage) or ongoing bleeding, PLT transfusions were administered when peripheral blood PLT counts were below 20 × 10⁹/l to 50 × 10⁹/l.
Study Endpoints

TEG Measurements

For comparative analysis of hemostatic function, transfusion efficacy and safety in study arm A and B, the primary endpoint was TEG measurements and 1-hour CCI. Secondary endpoints were 24-hour CCI. For comparative analysis of transfusion efficacy between the group of patients receiving gamma-irradiated PCs and those receiving non-irradiated PCs, 1-hour CI and CCI as well as 24-hour CI and CCI were calculated. PLT counts before transfusion and 1 h and 24 h after transfusion were obtained for each PLT transfusion to calculate 1- and 24-hour CCI, according to the following formula:

\[ \text{CCI} = \frac{(\text{post-transfusion PLT count} \times 10^9/l) - \text{pre-transfusion PLT count} \times 10^9/l)}{\text{body surface area} \times \text{PLT dose} \times 10^11} \]

Body surface area was estimated by the formula of DuBois and DuBois [21].

Safety Assessments

Patients that received gamma-irradiated PCs were monitored for 24 h after transfusion for adverse events (AEs) to evaluate safety. When an AE was reported, complementary information for assessment of causality and grade of severity was collected. If an AE was assessed as possibly related, probably related, or related to gamma-irradiated PCs, it was defined as an acute transfusion reaction (ATR). Bleeding assessments were performed prior to transfusion for each patient. In case bleeding was present prior to transfusion, post-transfusion bleeding status was also assessed. The respective clinical bleeding status was graded according to the WHO grading system (0, 1, 2, 3, 4; with grade 0 = no bleeding) [19].

Statistical Analysis

Statistical analysis was performed using chi-square test, Wilcoxon’s rank sum or log rank test where appropriate. A p value of less than 0.05 was considered significant.

Results

Demographic, Clinical, Laboratory Characteristics and Baseline Characteristics of Study Population

Between January 1, 2011, and December 31, 2012, a total of 40 patients admitted to the gamma irradiation side (arm A) and untreated control side (arm B) of the hematology ward were asked to participate in the study. The distributions of age, sex, height, and weight were similar in both groups. The vast majority of the patients in both groups were treated for malignant hematologic diseases, with no significant difference in the distribution of single diagnoses. The proportions of patients undergoing autologous and allogeneic hematopoietic stem cell transplantation (HSCT) were not significantly different between groups. A total of 40 patients (19 males and 21 females) had been enrolled into the study. All enrolled patients (aged 18–70 years) had a prior history of successful PLT transfusion with no transfusion reactions. All transfusions were ABO- and RhD-identical, by means of recipient having no antibodies incompatible with the RBC type of donor. Analysis of the primary and secondary outcomes was based upon the per protocol (PP) cohort, while the intention to treat (ITT) cohort was followed for safety data. Baseline demographics for the pooled ITT cohorts are summarized in table 1.

PLT Product Characteristics

A total of 20 PLT transfusions each were administered in the control group and in the treatment group; the PLT doses were within the range of 2.52–3.48 × 10^11 and 2.58–3.45 × 10^11 platelets per unit for the gamma-irradiated PCs and the non-irradiated PCs, respectively. Swirl was assessed positive (score 2) in all PCs tested. The product pH was 7.21 ± 0.06 for gamma-
clotting (R) and the angle of clot formation (α), whereas the effect on PLT clot strength and stability, the maximum amplitude (MA), persisted until the next day. No significant trends were observed for differences in pre-transfusion δ (p = 0.096), pre-transfusion MA (p = 0.105), pre-transfusion R (p = 0.630) in both study groups. At 1 h post transfusion, all efficacy variables were significantly different from pre-transfusion values for both the treatment (p < 0.05) and the control group (p < 0.17). At 24 h post transfusion, differences in R and δ were no longer significantly different from pre-transfusion values in patients treated with gamma-irradiated PCs (R, p = 0.343; δ, p = 0.204) as well as in

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Gamma irradiation group (n = 20)</th>
<th>Control group (n = 20)</th>
<th>p value† (ITT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>10/10</td>
<td>11/9</td>
<td>0.752</td>
</tr>
<tr>
<td>Age, years</td>
<td>52.5 (18–70)</td>
<td>54.5 (22–68)</td>
<td>0.871</td>
</tr>
<tr>
<td>Height, cm</td>
<td>167.5 (152–182)</td>
<td>169.0 (155–183)</td>
<td>0.786</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>67.6 (48.1–91.0)</td>
<td>68.5 (54.1–92.1)</td>
<td>0.981</td>
</tr>
<tr>
<td>Body surface area, m²</td>
<td>1.74 (1.39–2.12)</td>
<td>1.75 (1.49–2.14)</td>
<td>0.927</td>
</tr>
<tr>
<td>Blood group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O</td>
<td>7</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Rh factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>19</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td>4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>AML</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td>6</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MM</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>PCL</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

MDS = Myelodysplastic syndrome; AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; MM = multiple myeloma; AA = aplastic anemia; PCL = plasma cell leukemia; NS = not significant (p > 0.05).
† Data are reported as median (range).
†† Control group (ITT) compared to gamma irradiation group (ITT).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Gamma irradiation group</th>
<th>Control group</th>
<th>p value (1 h/24 h)†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>pre transfusion</td>
<td>1 h post transfusion</td>
<td>24 h post transfusion</td>
</tr>
<tr>
<td>R, min</td>
<td>9.85 ± 3.31†</td>
<td>8.30 ± 2.31†</td>
<td>9.31 ± 2.90†</td>
</tr>
<tr>
<td>α, °</td>
<td>39.90 ± 9.24†</td>
<td>49.55 ± 7.31†</td>
<td>42.65 ± 8.63†</td>
</tr>
<tr>
<td>MA, mm</td>
<td>39.30 ± 9.23†</td>
<td>47.81 ± 6.45†</td>
<td>45.75 ± 7.24†</td>
</tr>
</tbody>
</table>

Values are expressed as means ± SD.
† Gamma irradiation group (1 h post transfusion) compared to control group (1 h post transfusion); gamma irradiation group (24 h post transfusion) compared to control group (24 h post transfusion).
†† n = 19 due to missing TEG data for 1 patient.
NS = Not significant (p ≥ 0.05).

Irradiated and 7.24 ± 0.06 for non-irradiated PCs (p = 0.086), and the mean storage time was 2.15 ± 0.49 days for gamma-irradiated and 1.95 ± 0.51 days for non-irradiated PCs (p > 0.211). The RBC contamination was <3 × 10⁶/ml and the WBC content below 1 × 10⁶ per unit, meeting quality control requirements.

**Primary Endpoint**

**Hemostatic Function Evaluated by TEG and 1-Hour CCI**

PLT transfusion had an immediate but transient effect on initial clot formation that was reflected in the time to initiate clotting (R) and the angle of clot formation (α), whereas the effect on PLT clot strength and stability, the maximum amplitude (MA), persisted until the next day. No significant trends were observed for differences in pre-transfusion α (p = 0.096), pre-transfusion MA (p = 0.105), pre-transfusion R (p = 0.630) in both study groups.

At 1 h post transfusion, all efficacy variables were significantly different from pre-transfusion values for both the treatment (p < 0.05) and the control group (p < 0.17). At 24 h post transfusion, differences in R and α were no longer significantly different from pre-transfusion values in patients treated with gamma-irradiated PCs (R, p = 0.343; α, p = 0.204) as well as in...
the control group (R, p = 0.105; α, p = 0.064), whereas significant trends were observed in both groups for differences in MA (arm A, p = 0.004; arm B, p = 0.001). When comparing study arm A and B, none of the TEG measurement variables was significantly different at 1 h and at 24 h post transfusion. Hemostatic function variables, including the pre- and post-transfusion TEG variables, are summarized in table 2.

An additional primary endpoint of this study was whether gamma-irradiated PCs provided sufficient 1-hour CCI post transfusion compared to non-irradiated control PCs. Of the 40 patients of this study who received a PLT transfusion, 37 patients were eligible for the 1-hour CCI PP analyses (table 3).

### Secondary Endpoint

#### 1, 24-Hour CIs and 24-Hour CCI

In the PP population analysis, the mean 1-hour CI did not significantly differ between patients assigned to treatment with non-irradiated PCs and those receiving gamma-irradiated PCs. The results of the comparative analysis are given in table 3. Similarly, the 24-hour CI and 24-hour CCI of patients treated with gamma-irradiated PCs were not significantly different from those of patients receiving non-irradiated PCs (table 4).

### Additional Platelet Transfusions and Active Bleeding

The median time to the next PLT transfusion after the study transfusion was 2.2 days for the gamma-irradiated group and 2.4 days for the control group (p = 0.767, log-rank test). Within 15 days after the study transfusion, a median of 3 PLT transfusions was administered in both treatment groups. Bleeding was assessed within 12 h before and after each study transfusion. During the pre-transfusion assessments, three bleeding events (2 petechiae, 1 gingivorrhagia) were recorded before the gamma-irradiated PC transfusions and two

### Table 3. 1-hour CI and CCI – PP population

<table>
<thead>
<tr>
<th>Parameters of transfusion efficacy</th>
<th>Gamma irradiation group (n = 18)†</th>
<th>Control group (n = 19)§</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-transfusion platelet count (× 10⁹/l)</td>
<td>10.7 ± 4.15</td>
<td>11.0 ± 5.14</td>
<td>0.715</td>
</tr>
<tr>
<td>Median (range)</td>
<td>9.6 (5.0–25.1)</td>
<td>10.0 (4.3–29.1)</td>
<td></td>
</tr>
<tr>
<td>1-hour post-transfusion PLT count (× 10⁹/l)</td>
<td>29.9 ± 13.62</td>
<td>32.7 ± 13.68</td>
<td>0.346</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>28.8 (8.5–62.3)</td>
<td>33.8 (8.8–65.8)</td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>19.5 ± 10.63</td>
<td>21.6 ± 10.74</td>
<td>0.254</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>19.0 (3.5–49.9)</td>
<td>22.4 (2.9–48.7)</td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>11.6 ± 5.97</td>
<td>12.8 ± 6.33</td>
<td>0.171</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>11.1 (2.2–29.9)</td>
<td>13.0 (2.0–30.9)</td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>†Calculated for 18 patients: 2 patients had a single PLT transfusion with no post-transfusion PLT count. §Calculated for 19 patients: 1 patient had a single PLT transfusion with no post-transfusion PLT count. NS = Not significant (p &gt; 0.05).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 4. 24-hour CI and CCI – PP population

<table>
<thead>
<tr>
<th>Parameters of transfusion efficacy</th>
<th>Gamma irradiation group (n = 19)†</th>
<th>Control group (n = 18)§</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>24-hour post-transfusion PLT count (× 10⁹/l)</td>
<td>20.3 ± 10.15</td>
<td>22.1 ± 9.82</td>
<td>0.316</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>18.9 (8.0–46.1)</td>
<td>20.8 (7.9–50.4)</td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>9.8 ± 7.11</td>
<td>11.0 ± 6.61</td>
<td>0.242</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>8.7 (1.5–32.4)</td>
<td>9.8 (2.0–33.3)</td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>5.8 ± 4.05</td>
<td>6.6 ± 4.10</td>
<td>0.167</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>5.0 (1.1–19.4)</td>
<td>5.7 (1.4–21.1)</td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>†Calculated for 19 patients: one patient had a single PLT transfusion with no post-transfusion PLT count. §Calculated for 18 patients: two patients had a single PLT transfusion with no post-transfusion PLT count. NS = Not significant (p &gt; 0.05).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
(1 petechiae, 1 purpura) before the non-irradiated PC transfusions. Post transfusion, there were three bleeding events (3 petechiae or purpura) after gamma-irradiated PC transfusion and three bleeding events (3 petechiae or purpura) after non-irradiated PC transfusion. None of the transfusion bleeding events did exceed WHO grade 1 severity, and no inferences could be made about the relationship to PLT CI or MA modification.

**Additional RBCs Transfusions**

The majority of patients in both study arms did not require RBC transfusions within 24 h after the study transfusion. Only 7 of 20 (35%) patients in the control group and 8 of 20 (40%) patients in the group receiving gamma-irradiated PCs must be transfused with RBCs (p = 0.744).

**Safety Analysis**

Patients were observed for any AEs for 24 h after the start of the study PLT transfusion, and all AEs, whether or not classified as related to the study transfusion, were recorded. About 15% of the patients underwent at least 1 ATR within 24 h after the study platelet transfusion (15% in study arm A vs. 15% in study arm B), with the majority being allergic manifestations. All AEs occurred within 24 h after a transfusion; these AEs comprised a spectrum of signs and symptoms including fever (5% in study arm A vs. 10% in study arm B), chills (5% in study arm A vs. 0% in study arm B), skin rash (5% in study arm A vs. 0% in study arm B) and nausea/vomiting (0% in study arm A vs. 5% in study arm B). There were no statistically significant differences between treatment groups in the frequency of any AE deemed by the investigator as related to the study transfusion within the first 24 h or during the 4 days following study transfusion.

All patients were followed up from randomization until 30 days after study transfusion for serious AEs. All serious AEs were considered unrelated to the study transfusion. Two fatal serious AEs were considered not related to gamma-irradiated PCs. No case of transfusion-transmitted infection, TA-GVHD, or transfusion-related acute lung injury was observed. Three study patients died; two deaths occurred in the control group, and one death occurred in the treatment group. All other deaths were considered related to the patient’s underlying disease.

**Discussion**

The immunologic consequences of the transfusion of blood products can range from donor anti-recipient responses such as TA-GVHD to recipient anti-donor responses such as the production of alloantibodies, generation of regulatory responses, and responses that can eliminate the donor PLTs. While TA-GVHD only occurs in a limited number of transfusion recipients, the almost inevitable mortality associated with TA-GVHD led transfusion specialists to focus on preventing TA-GVHD [22]. Gamma irradiation of blood components is performed to reduce the risk for patients to develop this highly lethal complication which is caused by T lymphocytes in blood components [3]. As a result, gamma irradiation with 25 Gy was adopted as the standard treatment of blood products for the prevention of TA-GVHD.

To our knowledge, there are few studies reporting on the effect of gamma irradiation on apheresis PLTs [23, 24]. We found no difference in pH between gamma-irradiated and control PCs, which is in accordance with some previous reports. However, there are also studies that have reported differences in pH between irradiated and non-irradiated PCs [4]. Swirling was well maintained and at a similar level for irradiated and non-irradiated PCs. All PCs in our study complied with Chinese regulatory requirements (minimum PLT content of 2.52 × 10^11/unit).

The utility of TEG to provide rapid assessments of global hemostatic function in the operating theater and the emergency room is well established, and clot strength has repeatedly been reported to have the best correlation with clinically relevant blood loss [8, 25–27]. Its use in hematology-oncology patients with thrombocytopenia is relatively novel, but interest is growing [8, 28]. We found that both gamma-irradiated and untreated PCs significantly improved all TEG variables within 1 h of transfusion, indicating that the transfused PLTs were hemostatically active and that TEG was sensitive to the effects of a single PLT transfusion. All TEG variables indicated improved hemostatic function after transfusion of both gamma-irradiated and untreated PCs, with increases in α and MA most indicative of the role of PLTs in coagulation. MA was lower at 1 h post transfusion in gamma-irradiated PCs when compared to untreated PCs. Such thresholds for TEG variables have not yet been defined to guide transfusion practices in patients with thrombocytopenia. Comparing the two post-transfusion time points, MA in the group receiving gamma-irradiated PCs has not significantly changed while it has significantly dropped in the group receiving non-irradiated PCs.

This study is limited by its small sample size, and results must be interpreted with caution. Despite the small sample size, it is clear that TEG measurements demonstrated a hemostatic effect due to PLT transfusion in hematology-oncology patients with thrombocytopenia, and MA results were consistent with PLT counts. However, a common criticism of TEG is that it has not been correlated with more clinically relevant outcome measures such as bleeding events [8]. Apelseth et al. [18] recently reported that MA measured by TEG correlates with PLT CIs and bleeding, thus reflecting both PLT viability and functionality in hematology-oncology patients and demonstrating TEG’s clinical utility in this patient population.
We utilized other supporting endpoints directly indicative for hemostasis including active bleeding, AEs, and ATR. The safety profile was similar in both study groups for the first 24 h and for the 4 days following study transfusion. The AEs being classified as related to transfusion of gamma-irradiated PCs were infrequent, and all of them were of mild severity. The incidence of ATR was low too, and all reported ATRs were of mild severity. Our results are in line with our previous experience and with that of larger studies showing a generally low incidence of transfusion reactions associated with gamma-irradiated PCs. The ATRs observed were mild allergic reactions in the majority of cases. These events were all attributed to the progression of underlying illness and were considered unrelated to gamma irradiation of PCs. Our study showed that most bleedings were determined as bleeding score 0–1, with the majority involving the mucocutaneous organ system, and indicated that gamma irradiation of PCs was effective to support hemostasis and to prevent bleeding. Fewer patients had bleedings after transfusion than prior to transfusion. The study analyzed the safety and efficacy of gamma irradiation of PCs in a large cohort of hematologic patients. Gamma-irradiated PCs were found to be equivalent to non-irradiated PCs in terms of bleeding control. Most patients in this cohort had hematological diseases treated with high-dose chemotherapy, and about one third received autologous peripheral blood stem cell transplantations. Due to their very severe underlying diseases, the patients were at high risk for development of TA-GVHD. In the course of this study, no case of TA-GVHD was reported.

In conclusion, our study demonstrates similar hemostatic function and transfusion efficacy of gamma-irradiated PCs when compared to non-irradiated PCs in hematologic patients. Gamma irradiation treatment of PCs is safe in routine use even for such high-risk patients who are severely immunocompromised and have undergone stem cell transplantation.

Acknowledgments

We thank Dr. B-L Wang for his excellent technical and financial assistance and valuable advice during the preparation of this manuscript.

Disclosure Statement

The authors declare that they have no conflict of interest in the subject matter of the manuscript.
References


5. van der Meer PF, Pietersz RN: Gamma irradiation does not affect 7-day storage of platelet concentrates. Vox Sang 2005;89:97–99.


196

Transfus Med Hemother 2014;41:189–196

Zhu/Xu/Wang/Su